Abstract: A method of treating a non-human dermatological disorder, wherein the method comprises topically administering to a non-human dermatological disorder a therapeutically effective amount of a topical composition containing: (1) an active component comprising at least one salicylate derivative; and (2) at least one pharmaceutically acceptable solubilizer.

Abstract: In one embodiment, the present invention relates to a pesticide delivery system, containing a continuous film having a thickness from about 1 &mgr;m to about 1,000 &mgr;m and noncontinuous areas having sizes less than about 100 &mgr;m, the continuous film containing a particulate material wherein at least 90% by weight of the particulate material has a particle size of about 10 microns or less, and a pest control agent at least partially coating the particulate material.

Abstract: Stents with coatings comprising a combination of a restenosis inhibitor comprising an HMG-CoA reductase inhibitor and a carrier. Also provided are methods of coating stents with a combination of an HMG-CoA reductase inhibitor and a carrier. A preferred example of a restenosis inhibitor is cerivastatin. The stent coatings have been shown to release restenosis inhibitors in their active forms.

Abstract: The present patent describes a biocompatible composite made of a first fibrous layer attached to a three-dimensional inter-connected open cell porous foams that have a gradient in composition and/or microstructure through one or more directions. These composites can be made from blends of absorbable and biocompatible polymers. These biocompatible composites are particularly well suited to tissue engineering applications and can be designed to mimic tissue transition or interface zones.

Abstract: Medical devices such as intracoronary stents coated with a therapeutic substance are disclosed. In a preferred embodiment, an arterial site with obstructive coronary artery disease is treated via a therapeutic substance applied to an intraluminal stent and placed locally in the coronary artery. Improved porous designs polymeric films and coatings for stents, with or without a therapeutic substance, are also disclosed. By providing a separate sleeve and stent, various bioactive materials can be impregnated into the sleeve and combined with the stent, providing greater variety to treatment options, and significant improvements in regulatory protocols as new bioactive or therapeutic materials are produced. The present invention provides a stent that has a substrate and a degradable sleeve, and the sleeve itself is made of a carrier material, such as the polymeric materials and a bioactive compound.

Abstract: A composition to provide a calming stress hormone regulating and immune stimulation effect, which includes a combination of linoleic and linolenic acids, within certain ratios; at least one flavenoid; and at least one component having calming properties.

Abstract: A tissue product that has a relatively low level of lint and slough is provided. For example, the tissue product contains a flexible binder copolymer that is at least formed from an ethylenically unsaturated monomeric constituent and an unsaturated polysiloxane monomeric constituent.

Abstract: A method of manufacturing a bioactive fluid dose on an ingestible sheet, comprising the steps of advancing the ingestible sheet to a dispense position, and activating a fluid ejector to dispense essentially a drop of a bioactive fluid onto the ingestible sheet.

Abstract: The present invention provides a water insoluble, protective, adhesive skin patch useful for treating or preventing psoriasis, dermatitis, and/or eczema. The adhesive patch includes a backing that is treated with a sizing agent (e.g., a fluorocarbon solution, a silicone-containing compound, or a combination thereof). The present invention also provides a method for treating or preventing at least one of psoriasis, dermatitis, and eczema in a mammal (e.g., human) and a method for exfoliating the skin surface of a mammal.

Abstract: Methods and compositions are provided for enhancing the bioadhesive properties of polymers used in drug delivery systems. The bioadhesive properties of a base polymer are enhanced by incorporating a short chain polymer with one or more free carboxylic groups into the base polymer to enhance the ability of the base polymer to adhere to a tissue surface such as a mucosal membrane. The short chain polymers can be incorporated within a wide range of base polymers including proteins, polysaccharides and synthetic biocompatible polymers. In one embodiment, short chain polymers can be incorporated within base polymers used to form or coat drug delivery systems, such as microspheres, which contain a drug or diagnostic agent. The short chain polymers can either be solubilized and blended with the base polymer before manufacture or else used as a coating with base polymers over existing systems.

Abstract: Materials and methods for activating T lymphocytes with specificity for particular antigenic peptides are described, as well as the use of activated T lymphocytes in vitro for the treatment of a variety of disease conditions. In particular, a method for producing a synthetic antigen presenting cell line for activating T lymphocytes to a specific peptide is described.

Abstract: A double-headed, closed-mouth cough suppressant and cold relief device in which an individual having the symptoms of a cough is able to suppress the cough by inserting the device into an open mouth, and by sucking on one end of the device, is able to release a menthol medicament disposed within the device to thereby suppress a cough. Additionally, by sucking on another end of the device a eucalyptus medicament is released to thereby relieve a sore throat. By suppressing the cough, the device prevents the spread of germs to the immediate environment.

Abstract: A hydrocodone composition, a hydrocodone dosage form, and a method of administering hydrocodone are disclosed and indicated for hydrocodone therapy.

Abstract: An active pharmaceutical ingredient is combined with tannic acid to form a tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then blended with pharmaceutically acceptable excipients to form a granulate which is processed into a tablet or capsule to generate a therapeutic solid dosage form.

Abstract: A pharmaceutical composition of pranlukast having improved bioavailability is disclosed. The composition is formulated as a solid dispersion, preferably for oral administration. In one embodiment, the invention comprises an amount of pranlukast uniformly dispersed in an inert polymer carrier comprising at least one of hydroxypropylmethylcellulose or hydroxypropylcellulose. In another embodiment, the composition further comprises an amount of hydroxypropylmethylcellulose phthalate-50. A method for preparing the composition, an oral formulation comprising the composition, and methods of treating bronchial asthma and allergic rhinitis with the composition are also disclosed.

Abstract: An antibiotic product for delivering at least Amoxicillin or Clarithromycin that is comprised of three dosage forms with different release profiles with each of Amoxicillin and Clarithromycin being present in at least one of the dosage forms.

Abstract: The present invention is directed to a sustained release pharmaceutical composition in oral dosage form consisting essentially of a pharmaceutically effective amount of a medicament and a hydrophobic material in the absence of a lactose or hydrophobic carbohydrate polymer, said medicament being present in an amount greater than about 25% of the pharmaceutical composition and having a water solubility greater than about 1 gram per 10 mL of water at 25° C., said hydrophobic material having a melting point ranging from at least about 40° C. to about 100° C. at 1 atm pressure, and being present in an amount ranging from about 3% to about 20% by weight of the pharmaceutical composition and in an amount less than the of the medicament, and said hydrophobic material not being present in coating of said pharmaceutical composition; said pharmaceutical composition being prepared by direct compression in the absence of or melting the hydrophobic material or the use of high shear mixer.

Abstract: Disclosed is an oral controlled release macrolide pharmaceutical formulation. In a preferred embodiment, the formulation comprises a citrate salt of a preferred macrolide, clarithromycin. Also disclosed are methods for preparing, isolating and characterizing soluble and stable citrate salt of macrolides and use thereof in all solid dosage forms of macrolides.

Abstract: A method of coating an active material is provided. The method comprises contacting an active material with a film-forming composition comprising an aqueous dispersion of an amylose-alcohol complex, an insoluble film-forming polymer and a plasticiser at a temperature of less than 60° C. The method finds particular application in the preparation of dosage forms comprising active materials that are unstable at temperatures in excess of 60° C. The compositions prepared in accordance with the method can be used to deliver an active material to the colon.

Abstract: A pharmaceutical dosage form composition is composed of an ethylcellulose that has an ethoxyl range lower limit of 49.6%, an a viscosity of less than 53 cps and at least one active pharmaceutical ingredient. This dosage form is highly compressible and compactible forming harder tables or pellets with better release retardation than comparable prior art tablets.

Abstract: A method and compositions for reducing post-surgical adhesion formation/reformation in mammals following surgical injury to a body cavity or organs situated therein. The aqueous compositions comprising pentoxifylline and a polyoxyalkylene block copolymer are applied to the injured areas subsequent to surgical injury.

Abstract: The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical agent or cosmetic suspended in a frozen aqueous matrix and method for its preparation. The composition is stable for a prolonged period of time, preferably six months or longer and is suitable for parenteral, oral, or non-oral routes such as pulmonary (inhalation), ophthalmic, or topical administration.

Abstract: This patent refers to the use of a mixture of helium and oxygen for therapeutic purposes.

Abstract: Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a calcium glutarate compound. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to increase available calcium and contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.

Abstract: Compositions including zinc compounds and select amino acids in a carrier base, and methods of skin treatment with such compositions, are described. The compositions are useful for healing skin and minimizing the irritation incurred from contact with the zinc compound without loss of zinc availability during absorption into the integument.

Abstract: The present invention is directed to a zinc supplemented ORS and its use in the treatment of diarrhea.

Abstract: The present invention relates to a composite for the treatment of a variety of medical conditions, the composite comprising an oxidized glutathione-based compound, which has a disulfide bond, and a metal material, in particular where the metal is either platinum or palladium. The oxidized glutathione-based compound and metal material can be present in a ratio of 3000 to 1 and preferably 1000 to 1. The oxidized glutathione-based compound can be oxidized glutathione itself or salts or derivatives. A feature of the invention is that the composite has a more stabilized disulfide bond than the oxidized glutathione-based compound itself. Methods for preparing the composite are provided, such methods being beneficial in that the composite is provided in high yields and at high purity. Methods for treating various medical conditions with the composites of the present invention are also disclosed.

Abstract: The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs.

Abstract: A nutritional supplement includes flaxseed oil, ginger, sesame, citrus, garlic, tumeric, vitamins and minerals. The nutritional supplement preferably includes about 400 to 800 mg of flaxseed oil, about 50 to 100 mg of ginger, about 50 to 100 mg of sesame, about 50 to 100 mg of citrus, about 50 to 100 of garlic, about 10 to 30 mg of tumeric, about 6 to 10 mg of Vitamin C, about 1 to 5 IU of Vitamin E, about 0.25 to 1 mg of Vitamin B6, about 0.25 to 1 mg of niacin, about 3 to 6 mg of magnesium, and about 0.25 to 1 mg of zinc. The nutritional supplement may be used in a method of treating inflammation by administering to a patient in need thereof an effective dose of the nutritional supplement.

Abstract: A synthetic layered silicate material may be produced which exhibits tolerance to high levels of electrolytes and surfactants as measured by viscosity, hydration rate and clarity. The synthetic layered silicate material may produce similar or improved rheological properties when compared to natural hectorite at comparable or lower addition rates in select aqueous systems.

Abstract: A method for preventing veisalgia wherein an extract is prepared from artichoke and sarsaparilla containing a complex of polyphenols, flavonoids, and phytosterols. According to a preferred method, a dose of 1260 mg of extract is orally administered to a person prior to consuming alcohol. Subsequent to alcohol consumption another 1260 mg of extract is administered. The 1260 mg dose is adequate for most persons, is not critical, and can be scaled to a person's weight. The method as described results in complete elimination of veisalgia in more than 80% of individuals. As an alternate embodiment, the first three 420 mg quantities can be administered during consumption of alcohol. A further alternate embodiment provides an additional dose of 420 mg every hour during drinking after a period exceeding 4 hours, followed by the final dose of three 420 mg quantities at the cessation of alcohol consumption.

Abstract: The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosanthis kirilowii and Anemarrhena asphodeloides.

Abstract: Unique structured lipids obtained from interesterifying coconut oil with free fatty acids obtained from hydrolysis of triglycerides of vegetable source, said structured lipids rich in omega 6 polyunsaturated fatty acids and medium chain fatty acids and a process for the production of said structural lipids.

Abstract: The invention is directed to chemical processes of preparing fractions from North American ginseng (Panax quinquefolium) and pharmaceutical compositions containing these fractions. The products of the present invention may be used to stimulate the production of cytokines and/or antibodies, or as therapeutics targeted at conditions characterized by low immunity, such as the common cold, influenza, chronic fatigue syndrome, AIDS and cancer.

Abstract: A nutritional supplement includes eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), ginger, sesame, citrus, garlic and tumeric. The nutritional supplement preferably includes about 170 to 200 mg of EPA, about 113 to 133 mg of DHA, about 50 to 100 mg of ginger, about 50 to 100 mg of sesame, about 50 to 100 mg of citrus, about 50 to 100 of garlic, and about 10 to 30 mg of tumeric. The nutritional supplement may be used in a method of treating inflammation by administering to a patient in need thereof an effective dose of the nutritional supplement.

Abstract: The present invention features a method for constricting blood vessels, inhibiting angiogenesis, and/or reducing non-inflammatory redness in the skin by the topical administration of a composition comprising a Feverfew extract.

Abstract: An injection molding apparatus for producing a plastic product having a grain pattern thereon. The apparatus includes a female die having a grain pattern on an inner surface thereof, the female die further provided with a vacuum drawing mechanism for drawing a vacuum therethrough, and a male die having an injection aperture for injecting a thermal formable plastic material therethrough. The male die further includes a burr cutter adapted to slide fit in a gap between the male die and the female die and a guide pin with a spacer provided at four corners of the male die for controlling a distance between the male die and a female die.

Abstract: The present invention relates to an optical fiber recoating device, and to an improvement in the molds employed in this device. The optical fiber recoating device is provided for filling a recoating resin into molds, wherein semicircular mold grooves in molds into which the recoating resin is filled are longer than a bare fiber portion of an optical fiber, and an outer diameter of mold groove is larger than the outer diameter of semicircular sheath engaging grooves that engage a sheath of the optical fiber. As a result, a cylindrically shaped extending portion which extends to the sheath is formed to each end of the recoated sheath, so that joining strength of the recoated sheath is improved.

Abstract: An injection molding system is provided. The system includes a source of polymeric material, and an extruder including a screw rotatable within a barrel to convey polymeric material from the source in a downstream direction towards an outlet of the extruder. The system further includes an injection mold defining a cavity connectable to the outlet of the extruder, and an article positioned in the cavity. The article is to be molded along with the polymeric material in the injection mold.

Abstract: An extruder head has inner, middle, and outer annular outlets centered on a common axis and immediately adjacent one another, a flow splitter on the axis, first and second inlets axially upstream in an axial flow direction of the splitter, and a third inlet between the splitter and the outlets. A tubular inner passage centered on the axis extends in the direction from the first inlet around the splitter to the outer outlet and a tubular middle passage centered on the axis extends axially in the direction from the second inlet around the splitter to the middle outlet. An outer passage having an upstream portion axially downstream of the splitter extends transversely of the axis. A tubular downstream portion also axially downstream of the splitter extends coaxially around the inner and middle passages from the upstream portion to the outer outlet.

Abstract: Injection-moulding machine with at least one handling device, with an electronic stored-program control (SPC) for the injection-moulding machine and an electronic stored-program control for the handling device, characterized in that the stored-program control (SPC IMM, 17) for the injection-moulding machine (IMM) and the stored-program control (SPC R, 29) for the handling device (10) are realized on one and the same, common digital computer (30).

Abstract: The invention concerns a blow moulding machine comprising at least a blow mould (12), wherein is introduced a preform (14) previously produced by injection moulding, and a blow nozzle (22) for injecting pressurised air into the preform (14). The invention is characterised in that it is equipped with a device for orienting the preform in the mould, said device comprising a grip member (30) adapted to grip the preform (14) by its neck (18) when it is engaged in the mould (12); a device (66) for driving in rotation the grip member (30); a device for detecting (70) at least a reference angular position of the preform (14); and control means to cause the grip member to rotate until the detecting device detects the reference angular position of the preform.

Abstract: A casting mold half (5, 5a) for producing contact lenses comprises a mount (50) and an insert (51, 51a), which is arranged at one end of the mount (50) and can be connected to the mount (50) and which has a shaping surface (510) for the shaping of the front or rear surface of the contact lens to be produced. The insert (51, 51a) consists in the region of the shaping surface (510) of a material which is permeable to the energy crosslinking the starting material of the contact lens. Finally, a mask made of a material impermeable to the energy crosslinking the starting material is provided for spatially delimiting this energy. The mask comprises a separate surround (512) made of a material impermeable to the energy crosslinking the starting material of the contact lens, which surrounds the edge region of the shaping surface (510) of the insert (51, 51a).

Abstract: An air cooled or heated blow mold is shown having a mold cavity shell and a mold holder. The mold cavity shell is made by a process of nickel vapour deposition and so requires no hand finishing or polishing. The mold cavity shell has a cavity portion with a front face defining a cavity in the shape of a portion of a product to be molded. The mold holder is located rearwardly of the mold cavity shell and defines an inner wall spaced from the mold cavity shell cavity portion to define a heat transfer passage between the inner wall and the cavity portion. In use, air is passed through the heat transfer passage to transfer heat to or from the mold cavity shell.

Abstract: Machine for moulding containers (3a) made of plastic material, comprising an assembly (2) for extruding tubes (3) of plastic material, a blowing assembly (5), a mould for containing containers (3a), formed by two half-moulds (4a,4b) movable upon actuation of associated first means (100), in a longitudinal direction (X-X) and symmetrically with respect to a fixed axis (Z-Z) perpendicular to said longitudinal direction, the assembly formed by the mould (4) and the associated first actuating means (100) being movable, upon actuation of second actuating means (200), in a transverse direction (Y-Y) from a position corresponding to the extrusion assembly to a position corresponding to the blowing assembly and vice versa, wherein said first means for actuation in the longitudinal direction are of the electric type and means (110) for symmetrically adjusting the distance of the two half-moulds (4a,4b) from said fixed axis (Z-Z) are provided.

Abstract: Apparatus for gripping/holding parisons (2,2a) for blow-moulding machines (3), comprising support means (1) which can be connected to the devices for transporting the parisons, inside the machine and movable therewith, means (10) for gripping the neck (2a) of the parison (2) which are constrained to said support means and provided with means (15,15a) able to co-operate with associated means (20) for actuating the opening/closing movement of the said gripping means (10).

Abstract: A rotary device for a horizontal injection molding machine is configured in the form of a module frame which includes a base plate and a turntable rotatably mounted on the base plate. Drives are provided to move the base plate in longitudinal direction and to rotate the turntable. A fixed mold mounting plate of the injection molding machine can be mounted on a mounting structure of the module frame, whereas a moveable mold mounting plate is received in guides along the sides of the module frame.

Abstract: A closing unit for plastic molding machine includes a lower mold mounting plate, and an upper mold mounting plate, which are moveable via a pivot bearing between an open position and a closed position and can be locked in the closed position by a locking mechanism. The upper mold mounting plate is pivotable by a crank drive relative to the lower mold mounting plate, whereby the closed position is suitably commensurate with a dead center position of the crank drive. The lower mold mounting plate may be swingably mounted and includes locking members to secure the lower mold mounting plate in at least one pivot position. Further locking members are provided to secure the upper mold mounting plate in the open position.

Abstract: Provided is a bread product and a method of making the bread product having a shelf life of at least 60 days at ambient temperature and at least 6 months when stored frozen. Also provided is a sandwich having an extended shelf life, comprising two bread slices made according to the foregoing method, and a method of making the sandwich. The sandwich has a layer of a moisture-barrier substance disposed on one face of each bread slice, and at least one layer of a gelled food substance sandwiched between the barrier layers so as to separate the barrier layers from each other and form a sandwich having a shelf life of at least 45 days at ambient temperature and preferably 60 days at ambient temperature. In another aspect, the invention provides a nonmigrating, gelled filling suitable for use in the sandwich with the extended shelf life.

Abstract: Microfiltration of skim milk is carried out in combination with in-process pH reduction to provide a retentate useful for cheese making which is concentrated to a concentration factor of 7× to 12× and contains a ratio of calcium to total protein which is desired for the cheese, and a permeate which contains 40 to 80% of the whey protein of the skim milk being processed which is highly functional and typically contains little or no casein. Composition containing highly functional whey protein with no measurable fat or casein and no glycomacropeptides, rennet or starter cultures can be obtained; fruit beverages are disclosed which contain this composition.